Multiple Myeloma is a type of blood cancer that affects plasma cells, a specialized type of white blood cell found in the bone marrow. These abnormal plasma cells multiply uncontrollably and interfere with the production of healthy blood cells, potentially affecting bones, kidneys, and the immune system. Early diagnosis and specialized treatment can help control the disease, reduce complications, and improve quality of life.
Multiple Myeloma is a cancer of plasma cells, which are responsible for producing antibodies that help the body fight infections.
In this condition, abnormal plasma cells accumulate within the bone marrow and produce large amounts of abnormal proteins. Over time, these cancerous cells crowd out healthy blood-forming cells, weaken bones, and may damage organs such as the kidneys.
Multiple Myeloma is a chronic blood cancer that requires specialized diagnosis, treatment, and long-term monitoring.

Multiple Myeloma is more commonly diagnosed in older adults, particularly after the age of 60.

Having a close relative with Multiple Myeloma or related plasma cell disorders may slightly increase risk.

Individuals with Monoclonal Gammopathy of Undetermined Significance (MGUS) have a higher risk of developing Multiple Myeloma over time.

Long-term exposure to certain industrial chemicals may contribute to disease development.
If you are experiencing persistent bone pain, unexplained fatigue, recurrent infections, or abnormal blood test results, specialized evaluation is important.
Multiple myeloma is a cancer affecting plasma cells in the bone marrow.
Bone pain, fatigue, anemia, kidney issues, and recurrent infections.
Blood tests, bone marrow biopsy, imaging studies, and protein analysis.
While often considered chronic, many patients achieve long-term disease control.
Targeted therapy, chemotherapy, immunotherapy, and stem cell transplantation.
Targeted therapy, chemotherapy, immunotherapy, and stem cell transplantation.
Book Appoinment